Patients who tolerated the titration but find 2.4 mg uncomfortable can sometimes hold at 1.7 mg as a slower but still effective dose
ED is If you do develop ED, there are treatment options available that may help
Retatrutide and newer agents Retatrutide , a triple agonist targeting GLP-1, GIP, and glucagon receptors, is still in clinical development but early data suggest similar gastrointestinal side effect profiles
Each product in this article: adheres to allowable health claims and labeling requirements, per Food and Drug Administration (FDA) regulations is manufactured in facilities that adhere to current good manufacturing practices (CGMPs) established by the FDA is produced by a medically credible company that follows ethical, legal, and industry best standards is made by a company that provides objective measures of trust, such as having its supplements validated by third-party labs has been third-party tested to confirm purity and potency by an independent lab
The gastrointestinal side effects are similar to semaglutide but may be slightly better tolerated due to the GIP receptor activation, which has some gastroprotective properties
Fryer AA et al